
zzso zzso zzso is a newly developed zzso zzso which acts as an inhibitor of zzso zzso zzso Experimental zzso activity was demonstrated in a variety of zzso zzso A Phase I trial was undertaken on a daily zzso 5 zzso zzso 5) schedule in 22 zzso zzso zzso limiting toxicity was an oral zzso characterized by zzso red zzso zzso and zzso zzso The maximum tolerated dose is 320 zzso zzso 5 every three zzso The recommended dose for Phase II evaluation is 160 zzso zzso 5 every three zzso 

